Home
Drugs
Lenalidomide
Clinical Trials

Clinical Trials Related to Lenalidomide

Related studies linked through entity extraction aliases.

A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE1

A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE3

Chemotherapy Combined With Radiotherapy Versus Radiotherapy Alone for Solitary Plasmacytoma

Status: RECRUITING
Phase: PHASE2

Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

Status: RECRUITING
Phase: PHASE3

Safety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in R-R DLBCL Patients

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE1/PHASE2

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (VIPOR) for Diffuse Large B-cell Lymphoma Involving the Central Nervous System

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE1

A Study of Tazemetostat in Combination With Various Treatments in Participants With Blood Cancer.

Status: WITHDRAWN
Phase: PHASE1/PHASE2

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin Lymphoma

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE1/PHASE2

A Phase II Study of Zanubrutinib, Lenalidomide Plus R-CHOP as the First-line Treatment for Diffused Large B-cell Lymphoma

Status: UNKNOWN
Phase: PHASE2

A Multicenter In-class Transition Study of Ixazomib Combined With Pomalidomide and Dexamethasone or With Lenalidomide and Dexamethasone in Adults With Relapsed/Refractory Multiple Myeloma

Status: WITHDRAWN
Phase: PHASE4

Clinical Study on Anti-PD-1 Plus Lenalidomide and Azacitidine in Relapsed/Refractory Peripheral T-cell Lymphoma

Status: RECRUITING
Phase: PHASE2

A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal Impairment

Status: UNKNOWN
Phase: PHASE2

Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma

Status: RECRUITING
Phase: PHASE2

A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments

Status: RECRUITING
Phase: PHASE1

Isa-RVD Study in Patients With Newly Diagnosed Multiple Myeloma

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE2

A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma

Status: RECRUITING
Phase: PHASE3

Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma

Status: RECRUITING
Phase: PHASE2

A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE1

Upfront Chimeric Antigen Receptor T-Cell to Upgrade Response in Multiple Myeloma

Status: COMPLETED
Phase: PHASE2

ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE1/PHASE2